PSMA ADC in treatment of mCRPC post-chemo and post-abiraterone and/or enzalutamide

Data from an open-label Phase II trial of PSMA ADC — a fully human IgG1 antibody conjugated to monomethyl auristatin E (MMAE) — suggests that this agent has activity in treatment of metastatic, castration-resistant prostate cancer (mCRPC) patients who have already progressed on abiraterone acetate and/or enzalutamide. … READ MORE …

Does sequencing of therapy affect outcomes of treatment with sipuleucel-T + ADT in high-risk disease?

We still have very little knowledge about whether early prostate cancer immunotherapy with sipuleucel-T (Provenge) or other forms of immunotherapy might be beneficial in the management of patients with high-risk prostate cancer. … READ MORE …

Intermittent vs. continuous ADT: the results of the ICELAND trial

The results of early, large, randomized trials of intermittent (IADT) vs. continuous androgen deprivation therapy (CADT) have provided conflicting results. However, one of the flaws in early trials was the failure to ensure that men enrolled into these trials all actually had an optimal initial response to androgen deprivation (ADT). … READ MORE …

Tasquinimod not sufficiently effective in mCRPC in major Phase III trial

According to a media release issued early today in Europe, Active Biotech and Ipsen have terminated the development of tasquinimod for the treatment of prostate cancer after the drug failed to show sufficient clinical benefit in a major Phase III clinical trial. … READ MORE …

“Psychosocial interventions in prostate cancer offer limited benefits”

The heading above is the title of a Reuters-generated article on the Medcape Oncology web site. The article is based on a new review article just published in BJU International. … READ MORE …

Long-term survival of hormone-naive patients in biochemical failure post-surgery

A new paper in the European Journal of Nuclear Medicine and Molecular Imaging provides some interesting data on the long-term survival of men with progressive prostate cancer after initial treatment by radical prostatectomy. … READ MORE …

The side effects of radical prostatectomy: a new review

A new review article by a Danish research team in the Journal of Sexual Medicine has (arguably) brought a degree of clarity to what the authors refer to as “neglected” side effects consequent to radical prostatectomy. Unfortunately the average urologist probably doesn’t read the Journal of Sexual Medicine on a regular basis. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,257 other followers